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In the 1990s, the outlook for a metastatic renal-cell carcinoma
(mRCC) patient was particularly bleak, as the disease was
resistant to conventional chemotherapy and only small sub-
sets of patients responded to immunotherapy. This outlook
improved in 2005 with the introduction of sorafenib, the first
targeted therapy; it was followed by the development of other
tyrosine kinase inhibitors (TKIs): namely, sunitinib, pazopa-
nib, axitinib, the monoclonal antibody bevacizumab (directed
at vascular endothelial growth factor, VEGF) which was used
in combination with interferon (IFN) and the inhibitors of
the mammalian target of rapamycin (mTORis) everolimus
and temsirolimus. Despite the number of available options,
sequencing questions remain key, and the choice for first-
and second-line treatment is still controversial.
However, there is a consensus that VEGF inhibition is the
standard of care for first-line treatment in most cases. The
choice of first-line treatment is informed by the results of
large randomised clinical trials which have included prognos-
tic models in their design and analysis [1–3]. Recent guide-
lines have suggested that low- and intermediate-risk
patients are candidates for sunitinib, pazopanib or a combi-
nation of bevacizumab and interferon, while temsirolimus
should be an option for high-risk patients [4].
Second-line therapy for patients with mRCC of the clear-
cell type is still an evolving field. All the targeted agents
mentioned above have activity in patients previously ex-
posed to cytokine therapy; however, only the orally admin-
istered mTOR inhibitor everolimus is approved for patients
failing prior treatment with sorafenib and/or sunitinib [5].
Recent data have shown that axitinib, a selective VEGFR
TKI, significantly improves progression-free survival (PFS)
compared to sorafenib in patients who have previously
been treated with sunitinib [6]. Based on these two studies,
both agents are currently approved and are used as stan-
dard treatment in patients failing a first-line treatment
with VEGF inhibitors; they are part of the most recent
guidelines [4].Beyond second-line, there is no consensus and no ‘‘offi-
cially’’ approved drug. However, for the first time, the
European Society for Medical Oncology (ESMO) guidelines re-
cently opened the gate for third-line options [4]. This chapter
is intended to clarify possible options after second-line treat-
ment in mRCC.
Two sequences are currently standard of care, and approved
regimen: TKI (or VEGF inhibitor) followed by everolimus, or
TKI (or VEGF inhibitor) followed by axitinib. The proposed
third-line strategy will depend on this sequence (Table 1).
2. Treatment after TKI (or VEGF inhibitor)
followed by everolimus
There is no randomised study demonstrating the activity of
any approved agent after this sequence. However, there are
some retrospective data suggesting that another TKI can in-
duce clinical benefit in patients still eligible to receive tar-
geted agents [7,8]. In a retrospective database study, third-
line sorafenib appeared active and feasible after first-line sun-
itinib and second-line everolimus or temsirolimus in terms of
toxicity profile and median PFS [7]. Recently, 36 patients from
French sites who received a TKI after everolimus within the
RECORD-1 study have been reported [8]. The received TKI
after everolimus was sunitinib in 17 patients, sorafenib in 15
and dovitinib (TKI258) in four. The response rate with TKI
re-treatment was 8%, and the disease control rate (response
plus stable disease) was 75%. Median PFS with each compo-
nent of the TKI–everolimus–TKI sequence was 10.7 months
(range 1.8–28.5), 8.9 months (range 1.7–34.6) and 8.2 months
(95% confidence interval (CI) 5.2–11.9), respectively. Median
overall survival from the start of everolimus was 29.1 months
(95% CI 21.1 – not reached [NR]), suggesting a benefit in using
TKI in this setting.
Another option after the TKI–everolimus sequence is re-
challenge with the previous TKI [9]. Re-challenge with the
same agent has been examined in those with prior response;
for example, in a retrospective study, 23 patients who
exhibited long response with sunitinib first-line treatment
Table 1 – Third-line treatment in metastatic renal-cell cancer (mRCC).
Histology and setting Previous treatment Standard Option
Clear-cell third line Post 2 TKIs Everolimus Clinical trial
Post TKI and mTOR TKI (sorafenib, axitinib) Clinical trial
Non-clear-cell histology Clinical trial As for clear cell
170 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 6 9 –1 7 1were re-challenged with sunitinib after progression on prior
sunitinib were reported. Upon re-challenge, five patients
(22%) reached a PR. The median PFS with initial sunitinib
was 13.7 months and 7.2 months with re-challenge. Those
with >6-month interval between sunitinib treatments had a
longer PFS with re-challenge (median PFS, 16.5 versus
6.0 months, P = 0.03). Substantial new or increased severity
of toxicities was not reported during re-challenge.
Finally, newer TKIs have also demonstrated activity in this
setting. In a recent phase I/II clinical trial of dovitinib, an
inhibitor of multiple-receptor tyrosine kinases, including
fibroblast growth factor receptor (FGFr) and VEGF receptor
(VEGFr), in patients with mRCC refractory to standard thera-
pies, 8 of 10 patients previously treated with a TKI–everolimus
sequence achieved disease control, with one patient experi-
encing a partial response [10]. This has been convincing en-
ough to launch a large prospective phase III trial comparing
sorafenib and dovitinib in patients who have received one
TKI and onemTOR inhibitor (ClinicalTrials.gov. NCT identifier:
01223027). This trial, known as the GOLD trial, has completed
enrolment and will be reported shortly.
Interestingly, first-line PFS, with 6 months taken as cut-off
parameter, appears to be an important prognostic factor for
survival and thus for the likelihood of benefit of second-
and third-line treatments [11].3. Treatment after TKI (or VEGF inhibitor)
followed by axitinib
There is currently no evidence that a third TKI after two
TKIs has activity, although axitinib has shown some effi-
cacy after sunitinib and sorafenib, with a response rate of
7% and a PFS of 7.1 months in a small number of patients
[12].
By contrast, there is level I evidence that everolimus is ac-
tive after two TKIs, as recognised in the recent ESMO guide-
lines [4]. In the aforementioned phase III RECORD-1 trial,
everolimus was compared with placebo in patients following
sorafenib and/or sunitinib [5]. Among patients who received
one previous TKI median PFS was 5.4 months versus
1.9 months (HR, 0.32; P < 0.001), and among those who re-
ceived two previous TKIs median PFS was 4.0 months versus
1.8 months (HR, 0.32; P < 0.001) [13]. Although this might sug-
gest that everolimus is more active when given in second-line
than in third-line, it more strongly demonstrates that everol-
imus is still active when given after two TKIs.4. Future of treatment beyond second-line in
mRCC
TKIs as well as mTOR inhibitors have been shown to be active
in third-line treatment, depending on the previous sequence,as discussed above. In the future, several other options might
be available.
Dovitinib, which is currently in phase III, might become a
new standard if the ongoing GOLD study turns out to be posi-
tive. Interestingly, this study will also demonstrate whether
sorafenib is active in a randomised study after the sequence
TKI–mTOR.
There is a lot of enthusiasm for targeted immunotherapy,
such as anti-PD1 and/or anti-PDL1, in mRCC [14,15]. There is
an going phase III evaluating the efficacy of nivolumab
(BMS-936558), a T-cell checkpoint (PD-1) inhibitor, after one
or two TKIs, in comparison to everolimus (http://clinicaltri-
als.gov/ct2/show/NCT01668784). Overall survival is the pri-
mary endpoint of this study, and this trial will eventually
change the standard of care of mRCC treatment if the out-
come is positive.
Cabozantinib, a Met and VEGF receptor-2 inhibitor, has
shown promising activity in mRCC [16]. The activity of this
new TKI will be shortly evaluated in a large phase III trial, in
comparison to everolimus, after one or two TKIs. Obviously,
this treatment might in the future become a very attractive
strategy to overcome resistance.
5. Conclusion
There is evidence that treatment beyond the second line is ac-
tive in mRCC. Depending on the previous sequence used, both
mTOR inhibitors have shown efficacy. New strategies are
emerging and might change the landscape, dovitinib being
the first drug expected to be incorporated in future guidelines.
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